Grafalon

Grafalon is a rabbit‑derived anti‑thymocyte globulin for human use supplied as an injectable solution for intravenous administration. The product contains polyclonal antibodies that bind human T lymphocytes; the exact strength is not disclosed on the label. Classified as an immunosuppressive agent, Grafalon is prescribed in the European Union for prevention of organ‑transplant rejection and treatment of acute graft‑versus‑host disease in clinical practice.

Grafalon is used as an immunosuppressive therapy in specific transplant and hematopoietic settings.

- Prevention of acute rejection in kidney, liver, heart, and lung transplantation. - Prophylaxis of graft‑versus‑host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation. - Treatment of established acute GVHD when corticosteroids are insufficient. - Part of conditioning regimens prior to organ transplantation to reduce T‑cell mediated immune response. - Adjunctive therapy in selected autoimmune conditions under specialist guidance.

The safety profile of Grafalon reflects its immunomodulatory activity and includes a range of observed adverse events.

Common: - Fever, chills, or rigors during infusion - Nausea, vomiting, or abdominal discomfort - Mild rash or pruritus at infusion site

Serious: - Severe infection due to profound T‑cell depletion - Cytokine release syndrome with hypotension and respiratory distress - Hemolytic anemia, thrombocytopenia, or acute renal impairment

Clinicians should consider several precautions when prescribing Grafalon to minimize risks and ensure appropriate patient monitoring.

- Baseline screening for active infections, including viral, bacterial, and fungal pathogens. - Monitoring of complete blood count, liver and renal function before and during therapy. - Avoid use in patients with known hypersensitivity to rabbit proteins or previous anti‑thymocyte globulin reactions. - Caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Prophylactic antimicrobial therapy may be required to prevent opportunistic infections. - Assess cardiovascular status, as infusion may cause hemodynamic changes. - Ensure adequate hydration to reduce risk of renal complications.

Grafalon may interact with other medications, influencing immunosuppression or increasing adverse event risk.

Avoid: - Concurrent use of other potent immunosuppressants (e.g., high‑dose steroids, calcineurin inhibitors) without dose adjustment. - Live vaccines during treatment and for several weeks after the last dose. - Agents that significantly lower platelet count or cause hemolysis.

Use with caution: - Antimicrobial prophylaxis agents (e.g., trimethoprim‑sulfamethoxazole) due to additive bone‑marrow suppression. - Drugs affecting renal function (e.g., aminoglycosides, NSAIDs) as Grafalon can impact kidney perfusion. - Vaccinations with inactivated vaccines may have reduced efficacy; timing should be planned.